FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to the pharmaceutical industry, in particular to a combination containing a protein kinase C (PKC) inhibitor compound, which is 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]-1H-pyrrole-2,5-dione or a pharmaceutically acceptable salt thereof, and a mitogen-activated protein kinase (MEK) inhibitor compound, which is 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzimidazole-5-carboxylic acid 2-hydroxyethoxy-amide, or a pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for use in the treatment of a proliferative disease. Use of a pharmaceutical combination in the preparation of a medicament for the treatment of a proliferative disease. Use of a pharmaceutical combination in the manufacture of a medicinal agent for the treatment of melanoma. Method of using the pharmaceutical combination to treat a patient suffering from a proliferative disease. Combined formulation for use in the treatment of a proliferative disease, comprising (a) one or more standard dosage forms of a PKC inhibitor compound, which is 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]-1H-pyrrole-2,5-dione or a pharmaceutically acceptable salt thereof, and (b) one or more standard dosage forms of the MEK inhibitor compound, which is 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzimidazole-5-carboxylic acid 2-hydroxyethoxy-amide.
EFFECT: pharmaceutical combination has a synergistic interaction with respect to strong inhibition of cell proliferation.
34 cl, 6 dwg, 1 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS | 2012 |
|
RU2607944C2 |
PHARMACEUTICAL COMBINATIONS | 2017 |
|
RU2759669C2 |
PREPARATION OF AND FORMULATION COMPRISING A MEK INHIBITOR | 2013 |
|
RU2669391C2 |
COMBINATION THERAPY | 2013 |
|
RU2677245C2 |
MDM2 INHIBITORS AND COMBINATIONS THEREOF | 2016 |
|
RU2740091C2 |
8-ANILINOIMIDAZOPYRIDINES AND METHODS FOR USE THEREOF | 2008 |
|
RU2498985C2 |
COMPOSITIONS FOR TREATING CANCER USING ANTAGONISTS WHICH BIND TO THE PD-1 SIGNALING PATHWAY COMPONENT AND MEK INHIBITORS | 2015 |
|
RU2733735C2 |
COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
HETEROCYCLIC MEK INHIBITORS AND METHODS OF USING THEREOF | 2006 |
|
RU2414455C2 |
Authors
Dates
2018-12-14—Published
2013-11-26—Filed